Ofatumumab in AQP4-IgG Seropositive NMOSD — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Ofatumumab in AQP4-IgG Seropositive NMOSD — Stella

Recruiting

Back to Neuromyelitis Optica Spectrum Disorder trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Tangdu Hospital, Xi'an, Shaanxi

Key details

Phase

Early testing / Safety & dosing

Sponsor

Tang-Du Hospital

Collaborators

Henan Provincial People's Hospital

Enrollment target

~5 participants

Started

June 2022

Primary completion

April 2026

Age range

18 Years and older

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov